Next Article in Journal
Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada
Previous Article in Journal
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
 
 
curroncol-logo
Article Menu

Article Menu

Commentary

Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group

1
Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
2
Canadian Centre for Applied Research in Cancer Control, Canada
3
Centre for Health Economics and Hull York Medical School, University of York, York YO10 5DD, UK
4
ICES, Toronto, ON M4N 3M5, Canada
5
Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
6
BC Cancer, Vancouver, BC V5Z 1G1, Canada
7
Saskatchewan Cancer Agency, Regina SK S4W 0G3, Canada
8
CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
9
Department of Community Health Sciences, University of Manitoba, Winnipeg, MB R3E 0W3, Canada
10
Department of Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada
11
New Brunswick Institute for Research, Data and Training, University of New Brunswick, Fredericton, NB E3C 1N8, Canada
12
Cancer Care Program, Eastern Health, St. John’s, NL A1B 3V6, Canada
13
Department of Oncology, University of Calgary, Calgary, AB T2N 4N2, Canada
14
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC H3A 2T7, Canada
15
Ontario Health (CCO), Toronto, ON M5G 2L7, Canada
16
Prince Edward Island Cancer Registry, Government of Prince Edward Island, Charlottetown, PE C1A 9L2, Canada
17
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
18
Women’s College Hospital, Toronto, ON M5S 1B2, Canada
19
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M53 3M2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(3), 2046-2063; https://doi.org/10.3390/curroncol29030165
Received: 22 January 2022 / Revised: 2 March 2022 / Accepted: 11 March 2022 / Published: 17 March 2022
Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical care and healthcare policy. The CanREValue Collaboration is developing a framework for the use of RWE in cancer drug funding decisions. A Data Working Group (WG) was established to identify data assets across Canada for generating RWE of oncology drugs. The mapping exercise was conducted using an iterative scan with informant surveys and teleconference. Data experts from ten provinces convened for a total of three teleconferences and two in-person meetings from March 2018 to September 2019. Following each meeting, surveys were developed and shared with the data experts which focused on identifying databases and data elements, as well as a feasibility assessment of conducting RWE studies using existing data elements and resources. Survey responses were compiled into an interim data report, which was used for public stakeholder consultation. The feedback from the public consultation was used to update the interim data report. We found that databases required to conduct real-world studies are often held by multiple different data custodians. Ninety-seven databases were identified across Canada. Provinces held on average 9 distinct databases (range: 8–11). An Essential RWD Table was compiled that contains data elements that are necessary, at a minimal, to conduct an RWE study. An Expanded RWD Table that contains a more comprehensive list of potentially relevant data elements was also compiled and the availabilities of these data elements were mapped. While most provinces have data on patient demographics (e.g., age, sex) and cancer-related variables (e.g., morphology, topography), the availability and linkability of data on cancer treatment, clinical characteristics (e.g., morphology and topography), and drug costs vary among provinces. Based on current resources, data availability, and access processes, data experts in most provinces noted that more than 12 months would be required to complete an RWE study. The CanREValue Collaboration’s Data WG identified key data holdings, access considerations, as well as gaps in oncology treatment-specific data. This data catalogue can be used to facilitate future oncology-specific RWE analyses across Canada. View Full-Text
Keywords: real-world data; oncology; population-based real-world data; oncology; population-based
MDPI and ACS Style

Dai, W.F.; de Oliveira, C.; Blommaert, S.; Pataky, R.E.; Tran, D.; Aurangzeb, Z.; Kendell, C.; Folkins, C.; Somayaji, C.; Dowden, J.; Cheung, W.; Strumpf, E.; Beca, J.M.; McClure, C.; Urquhart, R.; McDonald, J.T.; Alvi, R.; Turner, D.; Peacock, S.; Denburg, A.; Mercer, R.E.; Muñoz, C.; Parmar, A.; Tadrous, M.; Takhar, P.; Chan, K.K.W.; on behalf of the CanREValue Collaboration. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group. Curr. Oncol. 2022, 29, 2046-2063. https://doi.org/10.3390/curroncol29030165

AMA Style

Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, Kendell C, Folkins C, Somayaji C, Dowden J, Cheung W, Strumpf E, Beca JM, McClure C, Urquhart R, McDonald JT, Alvi R, Turner D, Peacock S, Denburg A, Mercer RE, Muñoz C, Parmar A, Tadrous M, Takhar P, Chan KKW, on behalf of the CanREValue Collaboration. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group. Current Oncology. 2022; 29(3):2046-2063. https://doi.org/10.3390/curroncol29030165

Chicago/Turabian Style

Dai, Wei Fang, Claire de Oliveira, Scott Blommaert, Reka E. Pataky, David Tran, Zeb Aurangzeb, Cynthia Kendell, Chris Folkins, Chandy Somayaji, Jeff Dowden, Winson Cheung, Erin Strumpf, Jaclyn M. Beca, Carol McClure, Robin Urquhart, James Ted McDonald, Riaz Alvi, Donna Turner, Stuart Peacock, Avram Denburg, Rebecca E. Mercer, Caroline Muñoz, Ambica Parmar, Mina Tadrous, Pam Takhar, Kelvin K. W. Chan, and on behalf of the CanREValue Collaboration. 2022. "Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group" Current Oncology 29, no. 3: 2046-2063. https://doi.org/10.3390/curroncol29030165

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop